Evidence map›Paper›PMID 31036753›Full record

ArticleBiology open2019

Pioglitazone abolishes cognition impairments as well as BDNF and neurotensin disturbances in a rat model of autism.

Thiago B Kirsten, Renato C Casarin, Maria M Bernardi, Luciano F Felicio

Open access · goldAbstract read
In one paragraph

Article in Biology open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Thiago B KirstenDepartment of Pathology, School of Veterinary Medicine, University of São Paulo, São Paulo 05508-270, Brazil thik@outlook.com.ORCID http://orcid.org/0000-0002-4032-4355
Renato C CasarinGraduate Program of Dentistry, Paulista University, São Paulo 04026-002, Brazil.ORCID http://orcid.org/0000-0003-1743-5855
Maria M BernardiEnvironmental and Experimental Pathology, Paulista University, São Paulo 04026-002, Brazil.ORCID http://orcid.org/0000-0002-6860-9416
Luciano F FelicioDepartment of Pathology, School of Veterinary Medicine, University of São Paulo, São Paulo 05508-270, Brazil.ORCID http://orcid.org/0000-0002-9068-8317
Universidade de São Paulo · BRUniversidade Paulista · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have shown that exposure of rats to lipopolysaccharide (LPS) during gestation induces autistic-like behaviors in juvenile offspring and pioglitazone post treatment corrects social and communication deficits. The first objective of the present study was to evaluate the cognition of the rats, because this is also a behavioral sphere committed in autism. Second, biomarkers related to pioglitazone pathways and autism were studied to try to understand their mechanisms. We used our rat model of autism and pioglitazone was administered daily to these young offspring. T-maze spontaneous alternations tests, plasma levels of brain-derived neurotrophic factor (BDNF), beta-endorphin, neurotensin, oxytocin, and substance P were all studied. Exposure of rats to LPS during gestation induced cognitive deficits in the young offspring, elevated BDNF levels and decreased neurotensin levels. Daily postnatal pioglitazone treatment abolished cognition impairments as well as BDNF and neurotensin disturbances. Together with our previous studies, we suggest pioglitazone as a candidate for the treatment of autism, because it improved the responses of the three most typical autistic-like behaviors. BDNF and neurotensin also appeared to be related to the autistic-like behaviors and should be considered for therapeutic purposes.

Indexed as

LPSMaternal immune activationNeuropeptidesPrenatalT-maze spontaneous alternations test

Identifiers

PMID31036753
PMCPMC6550086
OpenAlexW2942674903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.